Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 10,301–10,400 of 15,747
Skarke, C., Lordan, R., Barekat, K., Naik, A. S., Mathew, D., Ohtani, T., Greenplate, A. R., Grant, G. R., Lahens, N. F., Gouma, S., et al. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001415 · Cited by 4
“A larger study to assess protection against SARS-CoV-2 infection after the second vaccine dose (BNT162b2) in 21,000 participants did not reveal effects speci fi c to sex, ethnicity, or age (Polack et al., 2020).”
Long-Term Care Research in the Context of COVID-19 Pandemic: A Bibliometric Analysis
Sun, Z., Chai, L., & Ma, R. (2023) · Healthcare · doi:10.3390/healthcare11091248 · Cited by 4
“Five references in cluster #5 were mainly about the safety and efficacy of SARS-CoV-2 Vaccine [38,39,43,55,56].”
BackgroundIn situ imaging of fluid dynamics and nanocarrier nucleation inside microfluidic mixing devices
Hauß, C., Erb, A., Most, J., Steinmann, J., Stark, R. W., Gier, S., & Windbergs, M. (2026) · Lab on a Chip · doi:10.1039/d5lc00947b · Cited by 4
Kumwichar, P., Chongsuvivatwong, V., Vasoppakarn, S., Atthakul, N., Nakhonsri, V., Ngamphiw, C., Khunkham, P., Janpoung, W., & Tongsima, S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.026 · Cited by 4
Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections
Quirk, G., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Lau, B., Liang, C.-Y., Burgess, J. L., Ellingson, K., Beitel, S. C., Romine, J. K., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02162-2 · Cited by 6
Value-based pricing of a COVID-19 vaccine
Gandjour, A. (2021) · The Quarterly Review of Economics and Finance · doi:10.1016/j.qref.2021.12.006 · Cited by 5
Using absolute risk reduction to guide the equitable distribution of COVID-19 vaccines
Fassler, E. A., Larkin, A., Nayar, K. R., & Waitzkin, H. B. (2022) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2021-111789 · Cited by 9
Rapid and Efficient Inactivation of SARS-CoV-2 from Surfaces using UVC Light Emitting Diode DevicePreprint
Dwivedi, V., Park, J., Grenon, S., Medendorp, N., Hallam, C. R. A., Torrelles, J. B., Martínez‐Sobrido, L., & Kulkarni, V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.20.440654 · Cited by 4
“Several prophylactics and therapeutics are undergoing human clinical trials.5 Currently, the United States Food and Drug Administration (US-FDA) has approved one therapeutic antiviral drug, Remdesivir, and a monoclonal antibody, MAb (Bamlanivimab) the treatment of SARS-CoV-2 infections under the Emergency Use Authoriz…”
BackgroundFriedman, M. R., Wingood, G. M., Krause, K. D., Krier, S. E., DʼSouza, G., Kempf, M.-C., Mimiaga, M. J., Kwait, J., Jones, D. L., Martinson, J. J., et al. (2024) · AIDS · doi:10.1097/qad.0000000000004053 · Cited by 3
Robust antibody and T cell responses tracked longitudinally in patients with long COVID
Metaxaki, M., Ram, R., Perera, M. R., Wills, M. R., Krishna, B. A., & Sithole, N. (2025) · Journal of General Virology · doi:10.1099/jgv.0.002172 · Cited by 4
“These observations agree with the abundance of publications showing antibody responses to SARS- CoV-2 vaccines and infections [58–62].”
Lasting memories of SARS-CoV-2 infection
Poon, M. M. L., & Färber, D. L. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210210 · Cited by 3
Impact of long-COVID on health-related quality of life in Japanese COVID-19 patientsPreprint
Tsuzuki, S., Miyazato, Y., Terada, M., Morioka, S., Ohmagari, N., & Beutels, P. (2021) · medRxiv · doi:10.1101/2021.09.27.21264225 · Cited by 5
Mbarek, H., Cocca, M., Al-Sarraj, Y., Saad, C., Mezzavilla, M., Al-Muftah, W., Cocciadiferro, D., Novelli, A., Quinti, I., AlTawashi, A., et al. (2021) · medRxiv · doi:10.3390/genes12111842 · Cited by 3
“With the development of the first generation of RNA based vaccines [16,17], along with the more standard adenovirus-based solutions [18,19], the end of the pandemic seems to be in sight, though we are aware that this is just the beginning of a more bearable coexistence with the virus.”
BackgroundMoriello, N. S., Buonomo, A. R., Scotto, R., Pinchera, B., Sarno, M., Fusco, L., Viceconte, G., Iuliano, A., Zappulo, E., Foggia, M., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13126 · Cited by 3
“As Pfizer-BioNTech and Moderna vaccines have demonstrated a 95% efficacy in preventing severe disease, the focus of physicians moved on other possible therapeutic approaches [1,2].”
Implementing vaccination policies based upon scientific evidence in Japan
Yoshikawa, T. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.075 · Cited by 3
“New vaccine platforms, such as messenger RNA and viral-vector vaccines, are being used for currently licensed vaccines [3,4].”
BackgroundProjeto S: A Stepped-Wedge Randomized Trial to Assess CoronaVac Effectiveness in Serrana, BrazilPreprint
Borges, M. D. C., Palácios, R., Brango, H., Conde, M. T. R. P., Patiño, E. G., Batista, A., Coutinho, B. M., Padua, G. G., de Moraes, G. R., Volpe, G. J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3973422 · Cited by 4
COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants
Selvam, S. P., Ramani, P., Ramya, R., Sundar, S., & Lakshmi, T. A. (2022) · Cureus · doi:10.7759/cureus.24927 · Cited by 5
“Though the efficacy after the first dose was only 51%, it gradually increased to 91% within the first seven days of the second dose [26].”
BackgroundLyons, J., Nafilyan, V., Akbari, A., Bedston, S., Harrison, E. M., Hayward, A. C., Hippisley‐Cox, J., Kee, F., Khunti, K., Rahman, S., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285979 · Cited by 4
Pulmonary Procedures in the COVID-19 Era
Schimmel, M., & Berkowitz, D. M. (2022) · Current Pulmonology Reports · doi:10.1007/s13665-022-00285-7 · Cited by 3
Domen, J., Abrams, S., Digregorio, M., Ngoc, P. V., Duysburgh, E., Scholtes, B., & Coenen, S. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09969-8 · Cited by 3
“The most prominent reported side-effects in the afore-mentioned trials included short-term, mild-to-moderate pain at the injection site, fatigue, headache, and muscle pains [3, 4].”
BackgroundPace, V. D., Bruzzone, B. M., Ricucci, V., Calcavecchia, N., Guarona, G., Giberti, I., Costa, E., Ogliastro, M., Galano, B., Nigro, N., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2258632 · Cited by 5
“According to clinical trials, T2 and T7 are the recommended time-points for the evaluation of vaccine effectiveness.(6,23) T2 (data reported above) and T7, with median values of RBD = 8204 (IQR: 4129–11912) U/mL and S1 = 4124 (IQR: 2124–6326) U/mL displayed the highest antibody values.”
BackgroundA descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines
Bausch-Jurken, M. T., Dawson, R. S., Ceddia, F., Urdaneta, V., Marks, M. A., & Doi, Y. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2402955 · Cited by 3
“…aged ≥18 years to receive mRNA-1273 and approximately 22,000 individuals aged ≥16 years to receive BNT162b2; with respective median follow-up times of 63 days and 2 months post-dose 2, there were no serious safety concerns and the vaccines were >94% effective against symptomatic infection [5,19].”
Reactogenicity of various COVID-19 vaccination regimens
Drapkina, O. M., Berns, S. A., Gorshkov, A. Y., et al. (2023) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3476 · Cited by 3
Forgeschi, G., Cavallo, G., Lorini, C., Balboni, F., Francesca, S., & Bonaccorsi, G. (2021) · Vaccines · doi:10.3390/vaccines9111332 · Cited by 3
mRNA COVID-19 Vaccination and Development of CMR-confirmed MyopericarditisPreprint
Kafil, T. S., Lamacie, M. M., Chenier, S., Taggart, H., Ghosh, N., DICK, A. J., Small, G. R., Liu, P. X., Beanlands, R. S., Mielniczuk, L. M., et al. (2021) · medRxiv · doi:10.1101/2021.09.13.21262182 · Cited by 4
“Despite this only one case of paroxysmal VT was reported in the BNT162b2 (BioNTech Pfizer) vaccine trial(18), and only a single paroxysmal episode was seen in 1 patient in our cohort, who remained asymptomatic.”
BackgroundRetractedSouan, L., Sughayer, M. A., Abualhour, M. M., et al. (2022) · Vaccines · doi:10.3390/vaccines10050642 · Cited by 3
“Introduction Vaccines against SARS-CoV-2 have been developed in an unexpectedly brief period [1,2].”
BackgroundIncreased Thrombotic Risk in COVID-19: Evidence and Controversy
Vita, A. D., Franceschi, F., & Covino, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134441 · Cited by 3
“The administration of mRNA vaccines (Comirnaty/BioNTech/Pfizer and mRNA-1273/Moderna) has been associated with a significantly lower rate of thrombotic complications [28].”
BackgroundMakan, N., Madhi, S. A., & Dangor, Z. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2471-6906 · Cited by 4
Adverse reactions in young children receiving the coronavirus disease 2019 vaccine
Matsumoto, N., Shimizu, J., Yokoyama, Y., Tsukahara, H., & Yorifuji, T. (2023) · Pediatrics International · doi:10.1111/ped.15696 · Cited by 3
“Adverse reactions were less frequent in this population compared with TABLE 2 Adverse reactions after primary dose of vaccine for young children aged 6 months to 1 year. adult populations, 27,28 and no individuals experienced fever above 39°C.”
Is COVID vaccine effective in patients with myeloid malignancy?
Mittelman, M. (2022) · British Journal of Haematology · doi:10.1111/bjh.18155 · Cited by 2
Kobayashi, T., Tokiya, M., Matsumoto, A., Nakano, T., Hirota, Y., & Hara, M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1348170 · Cited by 3
Quantification of Vaccine Waning as a Challenge Effect
Janvin, M., & Stensrud, M. J. (2024) · Journal of the American Statistical Association · doi:10.1080/01621459.2024.2408776 · Cited by 12
“In contrast, the causal graph in Figure 1 satisfies Assumptions 3–5.”
Doukas, P. G., Pierre, F. S., Karmali, R., Mi, X., Boyer, J., Nieves, M., Ison, M. G., Winter, J. N., Gordon, L. I., & Ma, S. (2023) · The Oncologist · doi:10.1093/oncolo/oyad121 · Cited by 3
Sayed, S. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100425 · Cited by 5
Frequency of Ipsilateral Axillary Lymphadenopathy After the Inactivated COVID-19 Vaccine
Turan, A., Kaplanoğlu, H., & Kaplanoğlu, V. (2022) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/1573405618666220310115711 · Cited by 3
Grand Challenges in Vaccine Delivery: Lessons Learned From the COVID-19 Vaccine Rollout
Foged, C. (2022) · Frontiers in Drug Delivery · doi:10.3389/fddev.2022.964298 · Cited by 3
Could fractional mRNA COVID-19 vaccines reduce myocarditis in adolescents?
Albano, L., & Ferrara, P. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102164 · Cited by 3
“Furthermore, taking as reference the dose-finding study of BNT162b2 mRNA vaccines safety and immunogenicity, it was expected a vaccine induced humoral response already frm a 1- to 5 μg dose, even if a 3- to 10-fold higher dose was found to elicit stronger antibody responses [4].”
School Asthma Care During COVID-19: What We Have Learned and What We Are Learning
Abrams, E. M., Jordan, K., & Szefler, S. J. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.11.020 · Cited by 3
“The vaccines are safe, immunogenic, and effective.(59,60) The U.”
BackgroundPotential Conscientious Objection to mRNA Technology as Preventive Treatment for COVID-19
Provost, P., Derôme, N., Linard, C. G., Massie, B., & Caron, J. (2022) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/ijvtpr.v2i2.41 · Cited by 2
“…a structurally stable protein (Lyons-Weiler, 2020; Vojdani & Kharrazian, 2020; Vojdani et al., 2021) with virus-independent cytotoxic effects (Pardi et al., 2015; Polack et al., 2020, Scioli Montoto et al., 2020; Suzuki et al., 2021) calls for the urgent need of pharmacovigilance studies.”
BackgroundInfluentialAn Update on Coronavirus Disease-19 Vaccines
Gupta, M., & Kapoor, I. (2021) · Journal of Medical Evidence · doi:10.4103/jme.jme_16_21 · Cited by 3
Assessment of clinical continuity strategies offered by dual-degree training programs in the USA
Spellicy, S. E., Mannon, E. C., Iness, A. N., Erickson, H. L., Camacho, M. B., Banerjee, A. K., Liu, J., Adami, A., & Weintraub, N. L. (2022) · Journal of Clinical and Translational Science · doi:10.1017/cts.2022.454 · Cited by 3
“Physician-scientists and their teams were essential in developing the Pfizer, Moderna, and AstraZeneca COVID-19 vaccines, respectively [2,3], and more than half of Nobel Prizes in Physiology or Medicine from 1997 to 2013 were awarded to physician-scientists or teams with at least one MD-PhD [4].”
BackgroundKlimek, L., Chaker, A. M., & Cuevas, M. (2021) · Laryngo-Rhino-Otologie · doi:10.1055/a-1372-3270 · Cited by 4
Schulte, B., Richter, E., Büning, A., Baum, M., Breuer, A., Zorn, J., König, J., Geiger, M., Eschbach-Bludau, M., Heuser, J., et al. (2024) · Eurosurveillance · doi:10.2807/1560-7917.es.2024.29.26.2300659 · Cited by 6
“Thus, the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was likely altered by the presence of vaccine-induced antibodies in most populations [1].”
BackgroundFarnsworth, C. W., O’Neil, C. A., Dalton, C., McDonald, D., Vogt, L. C., Hock, K. G., Arter, O. G., Wallace, M. A., Muenks, C. E., Amor, M., et al. (2023) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfad042 · Cited by 3
Controlling the first wave of the COVID–19 pandemic in Malawi: Results from a multi-round study
Banda, J., Dube, A. L. N., Brumfield, S., Crampin, A. C., Reniers, G., Amoah, A. S., & Helleringer, S. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003474 · Cited by 8
Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit
Yavuz, E., Turgut, K., Gülaçtı, U., Aydın, İ., Ozcan, O., SÖNMEZ, C., & Arslan, E. (2022) · Avicenna Journal of Medicine · doi:10.1055/s-0042-1750391 · Cited by 4
Matsumoto, Y., Murata, M., Ohta, A., Yamasaki, S., Ikezaki, H., Toyoda, K., & Shimono, N. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.11.014 · Cited by 3
Jeong, S., Hong, S., Oh, T.-H., Woo, S. H., Lee, W. J., Kim, D., & Jeong, W. J. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.04.022 · Cited by 4
Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients
Oganesyan, A. V., Menzulin, R., Surovoy, Y. A., Nikiforchin, A., & Zykov, K. A. (2021) · Critical Care Research and Practice · doi:10.1155/2021/5557302 · Cited by 4
Yamashita, E., Takita, M., & Kami, M. (2022) · Cureus · doi:10.7759/cureus.23380 · Cited by 3
“The initial clinical trials for the approval process commonly include healthy individuals or those with stable disease conditions [10], which may miss adverse events in patients at risk.”
BackgroundLin, S., Liu, H., Qi, Q., Ryan, I., Gao, D., Friedman, S., Xue, X. R., & Lawrence, D. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1419886 · Cited by 3
“The efficacy of the mRNA COVID-19 vaccine was first reported by Polack et al. in late 2020 (30).”
BackgroundAfifi, R. M., Harthi, M. K. A., Alharthi, B., et al. (2022) · Medical Science · doi:10.54905/disssi/v26i121/ms81e2017 · Cited by 3
Kim, J., Chang, E., Park, S. Y., Lee, D., Kang, C. K., Choe, P. G., Kim, N. J., Oh, M., Park, W. B., Lee, K.-H., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac196 · Cited by 3
COVID-19 post-vaccination recommendations for primary immunodeficiency
Roifman, C., & Vong, L. (2021) · LymphoSign Journal · doi:10.14785/lymphosign-2021-0023 · Cited by 2
Analysis of comprehensive biomolecules in critically ill patients via bioinformatics technologies
Matsumoto, H., Ogura, H., & Oda, J. (2024) · Acute Medicine & Surgery · doi:10.1002/ams2.944 · Cited by 2
“17,18 Research based on these methods will enable highly reproducible reverse translational studies based on clinical phenotypes and lead to drug discovery targeted to human molecules (Figure 4).”
Addressing COVID-19 Vaccine Hesitancy: The Role of Medical Students
Frisch, M. F., Chaudhary, W., Zhang, X., Parkas, V., & Forsyth, B. (2022) · Medical Science Educator · doi:10.1007/s40670-022-01670-2 · Cited by 5
Safety, Efficacy and Acceptability of SARS-CoV-2 Vaccines in Patients With Cancer
Chebel, R., Labaki, C., Farhat, M., & Kattan, J. G. (2021) · Future Virology · doi:10.2217/fvl-2021-0072 · Cited by 3
“This additional hesitation is fueled by the lack of evidence regarding the administration of SARS-CoV-2 vaccines in such a vulnerable population, as the pivotal studies that lead to the approval of these vaccines did not specifically report on oncological patients or those receiving any antineoplastic therapy [13,14].”
BackgroundShimada, T., Takada, J., Baba, A., Iwashita, M., Hayashi, T., Maeda, T., & Shimizu, M. (2024) · Internal Medicine · doi:10.2169/internalmedicine.2891-23 · Cited by 3
“Vaccination is considered an effective and safe means to control the spread of COVID-19 and reduce the risk of developing COVID-19 and its severity (12).”
BackgroundA live attenuated vaccine confers superior mucosal and systemic immunity to SARS-CoV-2 variants
Nouailles, G., Adler, J., Pennitz, P., Peidli, S., Alves, G., Baumgart, M., Bushe, J., Voss, A., Langenhagen, A., Pott, F., et al. (2022) · bioRxiv · doi:10.1101/2022.05.16.492138 · Cited by 2
“This observation is consistent with studies showing that adenovirus vector 447 vaccines can elicit stronger antibody responses than mRNA vaccines after a single dose 448 administration (33-35).”
ResultImmunological challenges of the “new” infections: corona viruses
Rees, A. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-812754-4.00017-0 · Cited by 5
Nanoparticle-based vaccines and future vaccine technologies
Vasudevan, S. S., Kandrikar, T. Y., Sayyed, A. A., Sarker, P., Nasir, N. S., Venugopalan, S., Mariajohn, R., Chavda, V. P., & Gondaliya, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00002-3 · Cited by 7
Anindita, J., Tanaka, H., Oyama, R., Matsumaru, A., Nakai, Y., Tange, K., Nagaoka, K., Nakanishi, H., Kawamura, T., Tanaka, T., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114414 · Cited by 6
Increased burden of booster shots for COVID-19 amidst vaccine hesitancy in Pakistan
Lal, P. M., Shaikh, O. A., Vohra, L. I., et al. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104360 · Cited by 3
“A two-dose regimen of the BNT162b2 vaccine provides 95% protection to people aged 16 years and above, against the novel coronavirus [4].”
Rational design of adjuvants boosts cancer vaccines
Li, X., Yamazaki, T., Ebara, M., Shirahata, N., & Hanagata, N. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.001 · Cited by 3
Chip-based digital PCR as a direct quantification method for residual DNA in mRNA drugs
Fan, W., Zhao, L., Yu, L., & Zhou, Y. F. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115837 · Cited by 3
Walsh, K. A., O’Donnell, H., O’Loughlin, M., Eames, H., Jiang, J., O’Brien, K. M., Broderick, N., O’Brien, K. K., Carrigan, M., Comber, L., et al. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2504 · Cited by 4
“Among the two reports with shorter follow up, the BNT162b2 (Pfizer/BioNTech) report by Polack et al. 34 ( n = 43,448 participants; mean follow ‐ up of 7.7 weeks) and the mRNA ‐ 1273 (Moderna) report by Baden et al. 27 ( n = 28,207 participants; median follow ‐ up of 9 weeks) found broadly…”
BackgroundResultInfluentialYam-Puc, J. C., Hosseini, Z., Horner, E., Gerber, P., Beristain-Covarrubias, N., Hughes, R., Rust, M., Boston, R. H., Ali, M., Rosello, E. S., et al. (2022) · medRxiv · doi:10.1101/2022.09.17.22280033 · Cited by 13
Tella, M. D., Nahi, Y. C., Paglia, G., & Geminiani, G. C. (2024) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acae031 · Cited by 3
(2021) · doi:10.1101/2021.12.02.21267205 · Cited by 3
“In December 2020, one year after the beginning of the pandemic, the first COVID-19 vaccine was shown to be safe and highly efficacious against the disease and its complications.(10) Given limited vaccine supply, most countries initially started with targeted vaccination of groups at greater risk of complications (e.”
BackgroundGicchino, M. F., Abbate, F. G., Amodio, A., et al. (2022) · Acta Paediatrica · doi:10.1111/apa.16481 · Cited by 3
Efficacy of COVID-19 Vaccines against the Omicron Variant of SARS-CoV-2: A Review
Rajsri, K. S., Singh, M., & Rao, M. (2023) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2023.00023 · Cited by 3
Madrid, J., Agarwal, P., Müller‐Peltzer, K., Askani, M., Benning, L., Selig, M., Diehl, P., Kalbhenn, J., Trummer, G., Utzolino, S., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01293-w · Cited by 6
“It is well-established that COVID-19 vaccination offers protection against COVID-19 infection, which could potentially lead to a reduction of ARDS among vaccinated individuals [10].”
BackgroundResultBadary, O. A. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2417 · Cited by 4
Schmiedeberg, K., Abela, I. A., Pikor, N. B., Vuilleumier, N., Schwarzmüller, M., Epp, S., Pagano, S., Grabherr, S., Patterson, A. B., Nussberger, M., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002575 · Cited by 5
Chiumello, D., Tavelli, A., Serio, L., Benedittis, S. D., Pozzi, T., Maj, R., Velati, M., Brusatori, S., D’Albo, R., Zinnato, C., et al. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01103-2 · Cited by 3
“Different types of vaccines have been developed, each with up to 90–95% efficacy for preventing COVID-19 and its related mortality [4–6].”
BackgroundHauser, D., Urda, L., Lang, C. M. R., Mittelholzer, C., Otte, F., Kipfer, E. T., Zhang, Y., Lett, M. J., Schebitz, C., Müller, R., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae527 · Cited by 3
“Immunocompromised individuals are often underrepresented or excluded from large vaccine trials [21, 22].”
BackgroundForoutan, F., Rayner, D. G., Oss, S., Straccia, M., de Vries, R., Raju, S., Ahmed, F., Kingdon, J., Bhagra, S. K., Tarani, S., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70100 · Cited by 3
“SOT recipients were excluded from clinical trials evaluating the safety and efficacy of COVID-19 vaccines [9].”
Pastre, A., Brass, O., Terreux, R., & Mégy, S. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c04980 · Cited by 4
Santimano, A. J., Al‐Zoubi, R. M., Al-Qudimat, A. R., Darwish, M. B. A., Ojha, L. K., Rejeb, M. A., Hamad, Y., Elrashid, M. A., Ruxshan, N. M., Omri, A. E., et al. (2024) · Intervirology · doi:10.1159/000538135 · Cited by 8
Equity and evidence during vaccine rollout: stepped wedge cluster randomised trials could help
Bell, K., Glasziou, P., Stanaway, F., Bossuyt, P. M., & Irwig, L. (2021) · BMJ · doi:10.1136/bmj.n435 · Cited by 4
Pirofski, L. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab374 · Cited by 3
“For Covid-19, the triumph of SARS-CoV-2 vaccines in preventing severe disease and death [11-13], the ability of monoclonal antibodies to prevent disease progression in individuals with”
BackgroundHumoral immunity trends in a hemodialysis cohort following SARS‐CoV‐2 mRNA booster: A cohort study
Goggins, E. S., Sharma, B., Ma, J. Z., Gautam, J., & Bowman, B. T. (2024) · Health Science Reports · doi:10.1002/hsr2.1858 · Cited by 2
A randomized phase 2 study on demeclocycline in patients with mild-to-moderate COVID-19
Iwahori, K., Nii, T., Yamaguchi, N., Kawasaki, T., Okamura, S., Hashimoto, K., Matsuki, T., Tsujino, K., Miki, K., Osa, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41051-2 · Cited by 4
Caucci, S., Corvaro, B., Tiano, S. M. L., Valenza, A., Longo, R., Marinelli, K., Ferreri, M. L., Spiridigliozzi, P., Salvoni, G., Bagnarelli, P., et al. (2021) · Vaccines · doi:10.3390/vaccines9101124 · Cited by 3
Bou-ouhrich, Y., & Charra, B. (2022) · Pan African Medical Journal · doi:10.11604/pamj.2022.43.124.32265 · Cited by 3
“Following the demonstration of effective prevention of COVID19 by several vaccines in phase-3 trials, they have been approved [6-9].”
InfluentialRNA therapeutics history and future perspectives
Duong, H., Hoang, M.-C., Nguyen, T.-H., Ngo, V.-L., & Le, V.-T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.01.004 · Cited by 3
Kappelman, M. D., Weaver, K. N., & Long, M. D. (2022) · PubMed · doi:10.17615/2k81-5y50 · Cited by 3
Clinical characteristics of SARS-CoV-2 vaccine-related acute appendicitis
Quint, E., Kukeev, I., Hazan, I., Grupel, D., Dukhno, O., Osyntsov, A., Sebbag, G., Guetta, O., & Czeiger, D. (2023) · Canadian Journal of Surgery · doi:10.1503/cjs.009322 · Cited by 3
Coulon, P.-G. A., Prakash, S., Dhanushkodi, N. R., Srivastava, R., Zayou, L., Tifrea, D. F., Edwards, R. A., Cesar, J. F., Schubl, S. D., Hsieh, L. L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.30.478343 · Cited by 5
Chemaitelly, H., AlMukdad, S., Ayoub, H., Altarawneh, H., Coyle, P., Tang, P., Yassine, H., Khatib, H. A., Smatti, M., Hasan, M. R., et al. (2022) · medRxiv · doi:10.1101/2022.07.26.22278045 · Cited by 2
Hara, S., Suzuki, T., Mizogaki, I., Miyazaki, T., Kondo, K., Arase, S., Suzuki, Y., Sato, S., & Ukai, K. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.104031 · Cited by 3
Unraveling Rising Mortality: Statistical Insights from Japan and International Comparisons
Kusunoki, H. (2025) · Healthcare · doi:10.3390/healthcare13111305 · Cited by 7
“It should be noted that much of the positive evidence regarding COVID-19 vaccines was generated in the early phase of their introduction (2021–2022) and primarily focused on populations in Western countries [9,40].”
Karabıber, E., Atik, Ö., Tepetam, F. M., Ergan, B., İlki, A., Karakoç-Aydıner, E., Özen, A., Özyer, F., & Barış, S. (2023) · Tuberkuloz ve Toraks · doi:10.5578/tt.20239705 · Cited by 3
“However, the efficacy in preventing severe disease has been demonstrated to be nearly 95% (25,26).”
BackgroundImpact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
Mikołajczyk, M., Lewandowski, R. A., & Goncharuk, A. G. (2022) · Vaccines · doi:10.3390/vaccines11010093 · Cited by 2
“The Moderna and Biontech-Pfizer vaccine brought promising results in clinical trials and were introduced for common COVID-19 prevention in the developed world [1,2].”
BackgroundSeija, M., García‐Luna, J., Rammauro, F., Brugnini, A., Trías, N., Astesiano, R., Santiago, J., Orihuela, N., Zulberti, C., Machado, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202630 · Cited by 3
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.